Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy

Novartis reports nine tumor cases possibly linked to Zolgensma gene therapy

Novartis confirmed that nine patients who received its spinal muscular atrophy gene therapy Zolgensma have developed tumors following treatment, with seven cases newly reported, raising serious safety concerns about the widely used pediatric drug.